Events

NEUROPORE THERAPIES (NPT®) PRESENTS POSTER AND ORAL PRESENTATION TITLED “NOVEL TLR2 SMALL MOLECULE ANTAGONISTS INHIBIT ALPHA-SYNUCLEIN-INDUCED PRO-INFLAMMATORY SIGNALING AND CYTOKINE RELEASE” AT GORDON RESEARCH CONFERENCE, NEUROBIOLOGY OF BRAIN DISORDERS August 5-10th, 2018  Rey Don Jaime Grand Hotel, Castelldefels, Spain  Click here for more information.

Please join us for the launch of our Symposia Series entitled, "Frontiers in Drug Discovery and Development for Neurodegenerative Diseases" with Dr. Thomas R. Insel July 24th, 2018  San Diego, CA  Click here for more information.

Neuropore Therapies (NPT™) will present a poster presentation entitled, "Structure based design and synthesis of novel Toll-like Receptor-2 (TLR2) antagonists" on April 30th at the 36th ACS National Medicinal Chemistry Symposium April 29th - May 2nd, 2018 Nashville, TN USA
Neuropore Therapies (NPT™) presents at the 2018 Advances in Alzheimer's and Parkinson's Therapies - an AAT-AD/PD Focus Meeting March 15th, 2018 Torino, Italy    Click here for more information.
Neuropore Therapies (NPT™) presents at the 20th Annual American Society for Experimental NeuroTherapeutics (ASENT) March 8 & 9th, 2018 Rockville, MD USA    Click here for more information.
Neuropore Therapies (NPT™) will hold an oral presentation at the 6th World CNS Summit entitled, “Targeting Autophagic Protein Clearance Mechanisms for the Treatment of Neurodegenerative Disease.” February 22nd, 2018 Boston, MA USA    Click here for more information.
Neuropore Therapies (NPT™) will hold an in-session event at EMBO Conference on Autophagy organizes "Autophagy induction as therapeutics for degenerative disease: A look into drug development of small molecule therapies by biopharmaceutical companies." September 26th, 2017 Cavat-Dubrovnik, Croatia    Click here for more information.
Neuropore Therapies (NPT™) CSO, Dr. Douglas Bonhaus will present a poster at the 2017 EMBO Conference on Autophagy entitled “Upregulation of autophagy for the treatment of Parkinson’s disease and other neurodegenerative diseases” September 26th, 2017 Cavtat-Dubrovnik, Croatia    Click here for more information.
Neuropore Therapies (NPT™) organizes 2016 Society for Neuroscience Satellite Event, "Targeting alpha-synuclein as a disease-modifying treatment for PD & synucleinopathies". November 13, 2016 San Diego, CA    Click here for more information.
Neuropore CEO, Dr. Dieter Meier presented at 10th Congress on Controversies in Neurology. March 17th-20th, 2016 Lisbon, Portugal
Neuropore COO, Dr. Douglas Bonhaus presented at the Michael J. Fox Foundation Parkinson’s Disease Therapeutics Conference. November 3rd-4th, 2015 New York, NY
Society for Neuroscience Neuropore researchers presented at the annual Society for Neuroscience Meeting. October 17th-21st, 2015 Chicago, IL
Presentation by Neuropore Founder, Dr. Eliezer Masliah at Grand Challenges in Parkinson’s Disease: A Synucleine. September 30th-October 1st, 2015 Grand Rapids, MI
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the German Society of Neuropathology and Neuroanatomy 60th Annual Meeting. August 26, 2015 Berlin, Germany
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Neuroscience School of Advanced Studies. August 24, 2015 Italy
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Columbia University PDF Center Seminar. August 13, 2015 NY, NY
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Medivation Seminar. August 7, 2015 San Francisco, CA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Banner Alzheimer’s Institute and ASU Biodesign Institute Seminar. July 28, 2015 Phoenix and Tempe AZ
Neuropore Founder and Scientific Advisor, Dr. Eliezer Masliah and CEO and President Dr. Dieter Meier attended the 19th International Congress Of Parkinson’s Disease and Movement Disorders. June 14th-18th, 2015 San Diego, CA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Intl Parkinson’s and Movement Disorders Society 19th Intl Parkinson’s and Movement Disorders Society Congress Understanding and treating proteinopathies. June 16, 2015 San Diego, CA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Intl Parkinson’s and Movement Disorders Society 19th Intl Parkinson’s and Movement Disorders Society Congress. June 16, 2015 San Diego, CA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Michael J. Fox Foundation Meeting. June 8, 2015 New York, NY
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 13th International Symposium. June 5, 2015 San Diego, CA
Neuropore Senior Director of Neuroscience, Dr. Diana Price Participated in Parkinson's Disease Imaging & Biomarkers Roundtable. May 11th-12th, 2015 Montreal, Canada
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the NIH NIA-NACA Meeting. May 12, 2015 Bethesda, MD
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Tulane University Neurosciences Program Seminar Series. April 15, 2015 New Orleans, LA
Neuropore Founder and Scientific Advisor, Dr. Eliezer Masliah and CEO and President Dr. Dieter Meier attended the International Congress on Alzheimer's and Parkinson's Disease. March 18th-22nd, 2015< Nice, France
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 12th International AD-PD conference, Prothena Symposium. March 21, 2015 Nice, France
Presentation by Neuropore Senior Director of Neuroscience, Dr. Diana Price at the World CNS summit: Modeling and Biomarkers. From Bedside to Bench (and back again): Iterative Translation for Improving Therapeutic Development February 17th-19th, 2015 Boston, MA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Mayo Clinic Neurosciences Department Seminar. February 16, 2015 Jacksonville, FL
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the International Parkinson and Movements Disorder Society. Alpha-Synuclein: the Gateway to Parkinsonism. February 13, 2015 Innsbuck, Austria
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the American Academy of Neurology Proteinopathy in Neurodegenerative Diseases. Breakthroughs in Neurology: Translating Today’s Discoveries into Tomorrow’s Clinics. January 23, 2015 Phoenix, AZ
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Cambridge Healthtech Institutes 14th Annual Cambridge Healthtech Institutes- PEPTALK. January 18, 2015 San Diego, CA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Banbury Center, Cold Spring Harbor Laboratory Lewy Body Dementia: Current Status, Future Directions. November 18, 2014 Cold Spring Harbor, NY
Society for Neuroscience
Neuropore researchers presented findings on NPT200-11 at the annual Society for Neuroscience Meeting.
November 15th-19th, 2014
  • Biophysical characterization of the interaction of NPT200-11 with alpha-synuclein.
  • Live imaging of alpha-synuclein aggregates in the retina of alpha-synuclein-GFP transgenic mice as a marker of alpha-synuclein pathology in the brain.
  • The novel alpha-synuclein stabilizer NPT200-11 improves behavior, neuropathology, and biochemistry in the murine thy1-ASYN transgenic model of Parkinson’s disease.
  • The novel alpha-synuclein stabilizer NPT200-11 reduces retinal deposits of ASYN-eGFP in a transgenic mouse model of Parkinson’s disease/Lewy body disease. 
Washington, DC
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 9th Annual Genetics Epidemiology of Parkinson’s Disease Consortium. September 12, 2014 Vancouver, BC, Canada
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Nutricia Symposium Alzheimer’s Association International Conference 2014. July 12, 2014 Copenhagen, Denmark
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the International Parkinson and Movement Disorder Society 18th International Congress. June 10, 2014 Stockholm, Sweden
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Keystone Symposia. April 16, 2014 Keystone, CO
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of North Texas Health Science Department of Cell Biology and Immunology. April 10, 2014 Fort Worth/Dallas, TX
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 13th International Symposium of Advances in Alzheimer Therapy. March 27, 2014 Geneva, Switzerland
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of Omaha. NeuroAIDS, Other Neurodegenerative Disorders and Mental Health – The Role of Brain Banks. March 21, 2014 Omaha, NE
Society for Neuroscience
Neuropore researchers presented at the annual Society for Neuroscience Meeting.
In vivo two-photon imaging of alpha-synuclein: Effects of a novel alpha-synuclein stabilizer in an eGFP-alpha-synuclein transgenic mouse model of Lewy Body disease.
Retinal scanning evaluations of alpha-synuclein-eGFP deposition in a transgenic mouse model of PD/DLB.
November 9th-13th, 2013 San Diego, CA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of Pennsylvania Annual Marian S Ware Neurodegenerative diseases Retreat. Transmission of Neurodegenerative Disease Pathologies. October 25, 2013 Philadelphia, PA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Expanding Prion Horizons 2013 Symposium. October 18, 2013 Fort Collins, CO
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the First International Novartis Parkinson’s Disease Symposium. September 14, 2013 Osaka, Japan
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Tokyo Metropolitan Institute of Medical Science Neurosciences Symposium. September 10, 2013 Tokyo, Japan
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Luxembourg Centre for Systems Biomedicine, & University of Luxembourg. May 21, 2013 Luxembourg
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Ever Neuropharma Elan Symposium. April 26, 2013 San Diego, CA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Functional Genomics of Parkinson's Disease and beyond Symposium. April 18, 2013 Tubingen, Germany
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Society of NeurolImmune Pharmacology 19th SNIP Scientific Conference. April 6, 2013 San Juan, Puerto Rico
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 11th International Conference on Alzheimer's and Parkinson's Disease. March 8, 2013 Florence, Italy
Neuropore researchers presented at International Conference on AD/PD. Development of a Novel Series of PI3K Modulators Designed to Promote Autophagy and the Cellular Clearance of Neurotoxic Peptides. March 6th-10th, 2013 Florence, Italy
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Michael J Fox Foundation Therapeutics Program Review. February 26, 2013 New York, NY
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 6th International Winter Conference on Alzheimer’s disease. December 9, 2012 Zuers, Austria
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the Department of Neurology University of Louisville. The Roth Lecture. November 16, 2012 Louisville, KY
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the University of Melbourne Brain Symposium. The John Cade Lecture. November 1, 2012 Melbourne, Australia
Neuropore researchers presented findings at the annual Society for Neuroscience Meeting. Novel organic compound targeting misfolded α-synuclein normalized calcium abnormalities in α-synuclein transgenic Parkinson’s Disease-like mouse model. October 13th-17th, 2012 New Orleans, LA
Presentation by Neuropore Founder, Dr. Eliezer Masliah at the 100 years of Lewy Bodies Conference. September 15, 2012 Munich, Germany
Alzheimer's Association International Conference
Neuropore researchers presented at the AAIC Meeting.
Neuroprotective effects of a novel abeta-protein stabilizer in an APP transgenic mouse model of Alzheimer’s disease. July 14th-19th, 2012 Vancouver, BC
Society for Neuroscience Neuropore researchers presented findings on NPT100-18A at the annual Society for Neuroscience Meeting. Novel structure based designed compound reduces accumulation of toxic alpha-synuclein and improves deficits in a transgenic murine model of PD/DLB. November 12th-16th, 2011